Study drug for B7-H3 positive neuroblastoma after relapse
Part of Cancer clinical trials.
This Phase 1 study tests TAA06, an injection that targets a marker called B7-H3 on neuroblastoma tumor cells. It is for children who have neuroblastoma that has come back or did not respond to prior treatment, aiming to see whether the treatment is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have neuroblastoma that has either come back after treatment or was not controlled after chemotherapy
- Your tumor tissue shows B7-H3 on the tumor cell surface (at least 1% of cells, with signal 1+ or higher)
- You can be expected to live at least 3 months and you are well enough for study procedures (score above 60)
- You have a tumor spot doctors can measure (and at least one lesion that can be treated with radiation, unless the only spots are in the bone marrow)
- Your heart, liver, kidneys, and oxygen levels meet lab/heart scan thresholds
- You (or your parent/guardian) understand the study and sign consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (called CNK-UT) for children whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if these cells can find and attack the cancer. Participation may be an option if your child's tumor has a specific marker (B7-H3) and their overall health is stable enough.
This trial tests a new immune therapy using your own cells (called B7-H3 CAR T cells) to treat solid tumors that haven't responded to other treatments. It may help children and young adults with certain cancers that are hard to cure.
This trial tests a new type of immune cell therapy called CAR T cells that target a protein called B7-H3 found on many solid tumors. It is for children and young adults whose cancer has come back or stopped responding to standard treatments.
This trial tests a combination of four drugs (chidamide, dinutuximab beta, irinotecan, and temozolomide) for children whose neuroblastoma has returned or isn't responding to standard treatment. It aims to see if this mix can shrink the tumor or stop it from growing.
This trial tests a new type of targeted radiation treatment for children and adults with neuroblastoma that has come back or not responded to other treatments. The radiation is attached to a substance that seeks out neuroblastoma cells, aiming to destroy them while limiting harm to healthy tissue.
This trial is testing different combinations of medicines for children with high-risk neuroblastoma that has come back. It has two paths: one for children whose disease has relapsed only once, and another for those whose disease has come back more than once. The goal is to find which treatments work best.
Hear when a new B7-H3-positive Relapsed/ Refractory Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.